Dianthus Therapeutics, Inc. (DNTH) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $5.94B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Marino Garcia |
| IPO Date | 2018-06-21 | CAGR | — |
| Employees | 92 | Website | dianthustx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | -0.01% | Total Yield | -0.01% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $5.82B | P/E | -25.59 | Forward P/E | -23.01 | PEG | — |
| P/S | 2209.33 | P/B | 2.15 | P/CF | -16.03 | P/FCF | -16.23 |
| Sales | $1.90M | Sales 1Y | -60.77% | Sales 3Y | -49.8% | Sales 5Y | inf% |
| EPS | $-4.15 | EPS 1Y | -96% | EPS 3Y | -99.03% | EPS 5Y | -99.43% |
| Sales QoQ | 64.36% | EPS QoQ | 5.88% | Sales QoQ Avg | 51.07% | EPS QoQ Avg | -120.93% |
| Gross Margin | 93.35% | Operating Margin | -19058.97% | Profit Margin | -2616.71% | ROCE | -18.48% |
| ROA | -2% | ROE | -4% | Altman Z Score | 85.39 | Piotroski Score | 2 |
| Current Ratio | 26.1 | Quick Ratio | 26.1 | Cash Ratio | 3.21 | Op. CF Ratio | -1.42 |
| Debt/Equity | 0 | Debt/Assets | 0 | Lt Debt/Equity | 0 | Lt Debt/Cap. | 0 |
| Intrst Cov. | — | Inventory Turnover | — | Asset Turnover | 0 | Receivables Turnover | 10.78 |
| Enterprise Value | $5.82B | P/E Ratio | -25.59 |
| Forward P/E | -23.01 | PEG Ratio | — |
| P/S Ratio | 2209.33 | P/B Ratio | 2.15 |
| P/CF Ratio | -16.03 | P/FCF Ratio | -16.23 |
| EPS | $-4.15 | EPS Growth 1Y | -96% |
| EPS Growth 3Y | -99.03% | EPS Growth 5Y | -99.43% |
| Revenue Growth 1Y | -60.77% | Gross Margin | 0.93% |
| Operating Margin | -190.59% | Profit Margin | -26.17% |
| ROE | -0.04% | ROA | -0.02% |
| ROCE | -0.18% | Current Ratio | 26.1 |
| Quick Ratio | 26.1 | Cash Ratio | 3.21 |
| Debt/Equity | 0 | Interest Coverage | — |
| Altman Z Score | 85.39 | Piotroski Score | 2 |
Dianthus Therapeutics, Inc. (DNTH) valuation & financials
Dianthus Therapeutics, Inc. (DNTH) has a market capitalization of $5.94B and trades at a price-to-earnings ratio of -25.6. It operates in the Healthcare sector (Biotechnology).
Dianthus Therapeutics, Inc.'s revenue grew -60.8% over the last year.
Dianthus Therapeutics, Inc.'s next earnings report is scheduled for November 5, 2026 after market close; analysts estimate EPS of $-0.94. Check the earnings calendar to see all companies reporting this week.
Dianthus Therapeutics, Inc. (DNTH) — frequently asked questions
When does Dianthus Therapeutics, Inc. (DNTH) report earnings next?
Dianthus Therapeutics, Inc. is expected to report earnings on November 5, 2026 after market close. Analysts estimate EPS of $-0.94.
What is Dianthus Therapeutics, Inc.'s market cap?
Dianthus Therapeutics, Inc. (DNTH) has a market capitalization of $5.94B.
What is DNTH's P/E ratio?
Dianthus Therapeutics, Inc. trades at a price-to-earnings ratio of -25.6, with trailing twelve-month EPS of $-4.15.
How fast is Dianthus Therapeutics, Inc. growing?
Dianthus Therapeutics, Inc.'s revenue grew -60.8% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)